You are here

Benlysta

GSK receives orphan drug designation for Benlysta to treat systemic sclerosis

GSK receives orphan drug designation for Benlysta to treat systemic sclerosis

Pharmaceutical Business Review

systemic sclerosis

Flag link:

GSK survey finds COVID, lack of early HCP conversations hitting lupus patients' care

GSK survey finds COVID, lack of early HCP conversations hitting lupus patients' care

Fierce Pharma

pharma marketing

Flag link:

AstraZeneca nabs FDA nod to challenge GSK's Benlysta with first-in-class lupus drug Saphnelo

AstraZeneca nabs FDA nod to challenge GSK's Benlysta with first-in-class lupus drug Saphnelo

Fierce Pharma

systemic lupus erythematosus

Flag link:

GlaxoSmithKline debuts DTC campaign for lupus med Benlysta as it looks to cement category lead

GlaxoSmithKline debuts DTC campaign for lupus med Benlysta as it looks to cement category lead

Fierce Pharma

DTC advertising

Flag link:

As GSK, Aurinia heat up the lupus nephritis category, analyst gauges doctors' first impressions

As GSK, Aurinia heat up the lupus nephritis category, analyst gauges doctors' first impressions

Fierce Pharma

lupus nephritis

Flag link:

After losing race for first to market in lupus nephritis, Aurinia taps Otsuka for voclosporin licensing pact abroad

After losing race for first to market in lupus nephritis, Aurinia taps Otsuka for voclosporin licensing pact abroad

Endpoints

Aurinia Pharmaceuticals

lupus nephritis

Flag link:

AstraZeneca lupus drug shows potential, but it may not be enough for FDA

AstraZeneca lupus drug shows potential, but it may not be enough for FDA

Biopharma Dive

Flag link:

GlaxoSmithKline's Benlysta eyes lupus sales boost after kidney trial win

GlaxoSmithKline's Benlysta eyes lupus sales boost after kidney trial win

Fierce Pharma

Flag link:

GSK gets FDA nod for Benlysta to treat pediatric patients with lupus

GSK gets FDA nod for Benlysta to treat pediatric patients with lupus

Pharmaceutical Business Review

systemic lupus erythematosus

Flag link:

GSK trials Benlysta/rituximab combo for lupus

GSK trials Benlysta/rituximab combo for lupus

Pharma Times

clinical trials

Flag link:

GSK gets go-ahead for new Benlysta formulation

GSK gets go-ahead for new Benlysta formulation

BioPharma Dive

systemic lupus erythematosus

Flag link:

Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta

Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta

Endpoints

Samsung Bioepis

Flag link:

5 Biotech Stocks With Major Catalysts in July

5 Biotech Stocks With Major Catalysts in July

Motley Fool

Puma Biotechnology

Flag link:

Benlysta maker GSK drafts soccer star Boxx to get lupus patients talking

Benlysta maker GSK drafts soccer star Boxx to get lupus patients talking

Fierce Pharma

Flag link:

GSK's lupus drug finally wins NICE backing, but only after discounts

GSK's lupus drug finally wins NICE backing, but only after discounts

BioPharma Dive

Flag link:

AstraZeneca, GlaxoSmithKline stake rival claims on new lupus therapies

AstraZeneca, GlaxoSmithKline stake rival claims on new lupus therapies

Fierce Biotech

Flag link:

AstraZeneca lupus drug produces positive results in trial

AstraZeneca lupus drug produces positive results in trial

Yahoo/Reuters

Flag link:

GlaxoSmithKline Launches Phase 3 Trial for Benlysta

GlaxoSmithKline Launches Phase 3 Trial for Benlysta

Motley Fool

ANCA-positive vasculitis

Flag link:

Biogen Sells Benlysta Rights

Biogen Sells Benlysta Rights

Yahoo/Zacks

Flag link:

Pages